Dr. Agarwal's Healthcare Q1 FY27 Revenue Surges 26% to ₹614 Crore; Launches 18 New Facilities
Dr. Agarwal's Health Care reported Q1 FY27 revenue of ₹614 crore, up 26% YoY. The company launched 18 new facilities, expanding its network to 285. EBITDA stood at ₹177 crore, up 25.2% YoY. High-end cataract surgeries and robotic procedures saw significant growth. The merger is expected to complete by mid-November.
The substantial revenue growth, record facility launches, and positive operational and clinical updates are material events that are likely to have a significant impact on investor sentiment and the company's market position.
The company reported strong year-on-year growth in revenue and EBITDA, along with a significant number of new facility launches and positive clinical advancements. The management commentary and financial performance indicate a healthy trajectory.
Dr. Agarwal's Health Care Limited announced a strong start to FY27 with its Q1 performance. The company reported a total income of ₹620 crore and revenue from operations of ₹614 crore, marking a significant 26% year-on-year growth. This growth was driven by a record launch of 16 new surgical facilities in the quarter, the highest ever. The company also saw a robust Ind AS EBITDA of ₹177 crore, up 25.2% year-on-year, with margins improving by 30 basis points to 28.5%. Profit After Tax (PAT) margin expanded by 127 basis points to 8.9%.
The company expanded its network by commissioning 18 new greenfield facilities in Q1 FY27, including one large tertiary facility and fifteen secondary facilities across various states, along with two primary facilities. This brings the total network to 285 facilities across 14 states and 5 union territories. During the quarter, Dr. Agarwal's served over 8.8 lakh patients and performed more than 90,000 surgeries.
Clinical excellence initiatives showed strong performance, with high-end cataract surgeries accounting for 29.3% of total cataract surgeries. Robotic cataract surgeries (Femto Cataract) grew by 33.4% year-on-year, and Lenticular Procedures (SMILE surgeries) increased by 36.2%. Retinal surgeries crossed 3,861 procedures, up 30% from last year, and corneal transplants reached 285 procedures.
The company also highlighted its innovative Pinhole Pupilloplasty (PPP) procedure, developed by its Chairman, Dr. Amar Agarwal, as a potential alternative to corneal transplants. This procedure requires no donor eye and has shown significant improvements in visual acuity for patients.
Regionally, the Southern region remained the largest market, contributing 63% of revenues with ₹387 crore, a 22.8% year-on-year growth. The Western region contributed ₹91 crore (up 24% YoY), and the Northern region showed the fastest growth at ₹57 crore (up 50.5% YoY).
Financially, the group's revenue from operations grew by 26% year-on-year to ₹614 crore. Doctor and employee costs increased slightly to 34% of total revenues due to new facility additions. Finance costs saw a reduction driven by lower interest on deferred consideration.
The company also provided an update on its merger, expecting it to be completed around mid-November.
What to do with a filing like this
Dr. Agarwal's Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Agarwal's Health Care Limited. Read the original for the full detail.